Chiesi, Pro­tal­ix's Fab­ry dis­ease treat­ment is ap­proved as Elfab­rio joins Fab­razyme, Galafold

The FDA has green­lit an en­zyme re­place­ment ther­a­py for adults with a rare, in­her­it­ed dis­ease in which ab­nor­mal de­posits of fat­ty sub­stances build up and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.